Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension, Renal Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan plus Spironolactone, Ambrisentan plus Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Intensive control of SBP, Standard control of SBP; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years and older
Enrollment: 9,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Intracranial Pressure Increase, Abdominal Compartment Syndrome
Interventions: Study Arm; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 72 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Hypertension Secondary to Kidney Transplant
Interventions: New Medication: Enalapril, Isradipine, Propranolol; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 5 Years to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions: Lifestyle Medicine Program, Medically Tailored Groceries; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Renal Insufficiency, Chronic Hypertension
Interventions: Spironolactone, Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana Institute for Medical Research; Other
Eligibility: 19 Years to 110 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: Paradise Ultrasound Renal Denervation Treatment; Device
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 39 more

Conditions: Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions: Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium; Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atrial Fibrillation, Hypertension
Interventions: AF ablation with Renal Denervation, AF ablation alone; Procedure
Lead sponsor: Siva Mulpuru; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 99 Years
Enrollment: 7,829 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Salt-sensitive Hypertension
Interventions: Fenoldopam; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Kidney Diseases
Interventions: Dietary education program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Diabetes, Hypertension, Diabetic Kidney Disease
Interventions: Pharmacist telehealth intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Dysfunction, Hypertension
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Artery Stenosis, Hypertension, Renovascular
Interventions: iCAST™ Rx Stent System; Device
Lead sponsor: Atrium Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 12
States / cities: Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Potassium estimation algorithm; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Kidney Transplantation, Medication Adherence, Hypertension
Interventions: SMASK, EnhancedSC; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography; Device · Other
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina

Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions: Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Kidney Diseases, Hypertension, Blood Pressure
Interventions: strict blood pressure control; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Hypertension,Essential
Interventions: Dehydrated Alcohol Injection, USP, Sham procedure; Drug · Procedure
Lead sponsor: Ablative Solutions, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

Systolic Blood Pressure Intervention Trial

Vasopressin in Intraabdominal Pressure Elevation

Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

Global Paradise System US Post Approval Study

Severe Sepsis in Children - IMPRESS-C

Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

Evaluation of Patients With Heart Disease Not Eligible for Research Protocols

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)

Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

Smart Phone Medication Adherence Saves Kidneys--SMASK

Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4

Contributions to Hypertension With Androgen Deprivation Therapy

Pilot to Examine Risk and Feasibility of Remote Management of BP From Childhood Into Early Adulthood

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)